FDA voices concern over bills that restrict biosimilars

08/30/2013 | Drug Store News · BioPharmaReporter.com

Biosimilars face a very high standard for approval, and efforts in state legislatures to undermine faith in the process that will bring them to market could hurt patients in the long run, FDA spokeswoman Lisa Kubaska said. Although the agency doesn't take stands on specific state measures, any biosimilars that are approved must be interchangeable products under a 2010 federal law, she said.

View Full Article in:

Drug Store News · BioPharmaReporter.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA